A Comparison of the Neuroprotective Efficacy of Newly Developed Oximes (K156, K203) and Currently Available Oximes (Obidoxime, HI-6) in Cyclosarin-poisoned Rats

Kassa, Jiří; Žďárová Karasová, Jana; Tesařová, Sandra; Kuča, Kamil; Musílek, Kamil

doi:10.14712/18059694.2017.27

Acta Medica > Archive > 2008, Vol. 51 > Issue 4 > A Comparison of the Neuroprotective…

Acta Med. 2008, 51: 215-221

https://doi.org/10.14712/18059694.2017.27

A Comparison of the Neuroprotective Efficacy of Newly Developed Oximes (K156, K203) and Currently Available Oximes (Obidoxime, HI-6) in Cyclosarin-poisoned Rats

Jiří Kassa^a, Jana Žďárová Karasová^a, Sandra Tesařová^b, Kamil Kuča^c, Kamil Musílek^a

^aUniversity of Defence, Faculty of Military Health Sciences, Department of Toxicology, Hradec Králové, Czech Republic
^bThe 7th Field Hospital of the Czech Army, Hradec Králové, Czech Republic
^cUniversity of Defence, Faculty of Military Health Sciences, Center of Advanced Studies, Hradec Králové, Czech Republic

Received August 1, 2008
Accepted December 1, 2008

The neuroprotective effects of newly developed oximes (K156, K203) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with cyclosarin were studied. The cyclosarin-induced neurotoxicity was monitored using a functional observational battery 24 hours after cyclosarin challenge. The results indicate that a newly developed oxime K156 is able to counteract slightly cyclosarin-induced neurotoxicity while another newly developed oxime K203 is completely ineffective in reducing cyclosarin-induced neurotoxic signs and symptoms. The neuroprotective efficacy of K156 is comparable with commonly used obidoxime and oxime HI-6. Thus, none of the newly developed oximes achieves better neuroprotective efficacy than both commonly used oximes. They are therefore not suitable replacements for antidotal treatment of acute poisonings with cyclosarin.